Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. We believe that our array of technology platforms uniquely positions us among other biotechnology companies to advance precision medicine.
In the company’s own words · 10-K filed Mar 25, 2026 · SEC EDGAR
Business segments
Q1 2026 · $23.3MThe company’s own SEC segment disclosure.
- Papzimeos$21.6M93%
- Service$1.4M6%
- Exemplar$237.0K1%
Precigen, Inc. (PGEN) reported revenue of $23M in Q1 2026 (quarter ended March 31, 2026), up 1634% from the same quarter a year earlier. That came with net loss of $7.9M. For the full year FY2025, revenue was $9.7M (+147% year on year) and net income −$251M. Its largest product in 2026-Q1 was Papzimeos at $22M, 93% of the disclosed total, just ahead of Service at 6.1%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.